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Purpose: We assessed the combined use of Staphylococcal Enterotoxin B (SEB) superantigen pre-treatment along with
allogeneic bone marrow transplant (BMT) to induce immune suppression condition and inhibit corneal keratoplasty
rejection in mice.
Methods: BALB/C (H-2d) mice were both BMT and corneal allografts donors and C57BL/6(H-2b) mice were recipients.
Prior to BMT, recipients received single injections of either SEB, cyclophosphamide (CYP), or normal saline (NS).
Allogenic corneal penetrating keratoplasty was performed 7 days after BMT. Bone marrow chimerisms in recipients
(donor major histocompatibility complex-II H2-d) were determined on Days 14, 28, and 56 post-BMT. Recipient immune
response was assessed by mixed lymphocyte reactions (MLR) using splenocytes from C57BL/6 mice as responders in
co-culture with stimulator cells from C57BL/6 (isogeneic), BALB/C (allogeneic), or CBA/1(third party) mice. Cluster of
differentiation 4 receptors positive (CD4+) and CD8+T cells in recipient mice were evaluated. Corneal graft survival was
assessed using Kaplan–Meier survival curves.
Results: SEB pre-treatment induced higher levels of hematopoietic chimerism on Days 14, 28 and 56 post-BMT than did
CYP or NS pre-treatment. Mean corneal allograft survival was significantly prolonged with group SEB-BMT (20.3±7.6
days) compared to group CYP-BMT (13.0±4.0 days) and NS-BMT (9.0±2.2 days). SEB-BMT mice splenocytes had
diminished MLR responses compared to CYP-BMT or NS-BMT mice. CD4+ and CD8+ T cells in peripheral blood and
spleens were significantly reduced in group SEB-BMT mice.
Conclusions: BMT after SEB pre-treatment could promote mixed chimerism, which inhibited allogeneic cornea transplant
rejection. This should possibly relate to CD4+ and CD8+ T cell deletion and acquiring donor-specific immunosuppression.
Solid organ transplantation is an accepted treatment for
end-stage organ failure. Orthotopic allogeneic corneal grafts
are among the most successful of solid organ transplants [1].
However, a significant percentage of these grafts are rejected
at least once due largely to the unique biology involved as
compared to transplanting solid vascularised organs for which
systemic immunosuppression is used [2]. When allogeneic
corneas  are  placed  in  mouse  eyes  with  neovascularized
corneas,  a  situation  resembling  high-risk  eyes  in  clinical
ophthalmology, the incidence and vigor of graft rejection are
increased,  indicating  compromised  immune  privilege  [3].
Thus,  methods  are  needed  to  overcome  the  unique
immunological barriers involved with corneal transplantation
without long-term systemic immunosuppression, which can
often have debilitating and possibly fatal consequences [4].
One approach is to induce donor-specific immune tolerance
in a graft recipient.
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Mixed  chimerism  and  donor-specific  tolerance  across
major  histocompatibility  complex  (MHC)  barriers  can  be
induced by donor bone marrow transplantation (BMT) under
short-term immunosuppression [5]. However, if conventional
doses of bone marrow are used, recipient conditioning with
total body irradiation or cytotoxic drugs is usually required.
To  decrease  the  toxicity  associated  with  pre-treatment
regimens,  various  protocols,  including  anti-lymphocyte
serum, chemotherapeutic drugs and monoclonal antibodies,
have  been  used  to  induce  bone  marrow  macrochimerism,
primarily in murine models [6-13].
In previous investigations, we used treatments with the
superantigen Staphylococcal enterotoxin B (SEB) to suppress
immune rejection during corneal transplantation [14-17].
SEB  is  a  bacteria-derived  superantigen  that  bypasses
classical donor MHC class I and II restrictions and interacts
directly  with  both  cluster  of  differentiation  4  receptors
positive (CD4+) and CD8+ T cells. Of note, T cells respond to
SEB stimulation with profound cytokine production by both
CD4+ and CD8+ T subpopulations, which results in T-cell
deletion  and  anergy.  We  recently  showed  that  SEB
significantly prolonged the survival time of allografts in high
risk rat corneal allo-transplantation, possibly due to T cell
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974deletion and the acquisition of non-specific tolerance [14].
This  suggested  that  non-myeloablative  pre-treatment  with
SEB could provide a certain period of immunosuppression
and raised the question of if this period was sufficient for
donor bone marrow to establish a chimera during a period of
T cell depletion and anergy.
In  this  study,  we  investigated  if  short-term
immunosuppression and anergy induced by BMT after SEB
pre-treatment  could  improve  the  rate  of  chimeric
establishment  and  corneal  allograft  survival  in  a  murine
model.  As  a  positive  control,  we  used  cyclophosphamide
(CYP), a commonly used chemotherapeutic drug that can
induce allograft tolerance [18-20].
METHODS
Mice: Six to 8 week-old female BALB/c (H-2d) and C57BL/
6 (H-2b) mice were purchased from The Capital Medical
University (Beijing, China). BALB/c mice were used as both
bone marrow and cornea donors and C57BL/6 mice were
recipients. They were maintained in a specific pathogen-free
facility at the vivarium of the Capital Medical University and
treated  according  to  the  criteria  outlined  in  the  National
Guidelines for the Care and Use of Laboratory Animals.
Pre-treatment and bone marrow transplantation: To prepare
bone marrow cells (BMCs) for transplantation, unseparated
BMCs were harvested from the tibias and femurs of fully
MHC-II  and  minor  histocompatibility  antigen-mismatched
female BALB/c donors [21]. Cells in suspension were counted
using trypan blue exclusion (Life Technologies, Inc.). After
centrifugation at 1,200× g at 4 °C for 10 min, the BMC pellet
was resuspended in 2 ml PBS and adjusted to 4×108 cells/ml.
Age-matched female C57BL/6 mice were injected with a total
of 25×106 cells/mouse of unseparated BMCs (Day 0) via a
caudal vein using a 26-G needle (BD, Inc., Franklin Lakes,
NJ).
As  outlined  in  Figure  1,  three  different  non-
myeloablative pre-treatments combined with or without BMT
were used for mice that were to receive corneal transplants.
Recipient  C57BL/6  mice  were  divided  into  6  groups  for
different pre-treatments (20 mice/group): SEB treated; CYP
treated  (positive  control  group);  and  normal  saline  (NS)
treated  (untreated  control  group).  SEB  (Department  of
Immunology, General Hospital of PLA, Beijing, China) was
dissolved in saline and intraperitoneally injected at a single
dose  of  75  μg/kg  at  7  days  before  BMT  (Day  −7).  CYP
(Sigma-Aldrich, St. Louis, MO) was dissolved in saline and
intraperitoneally injected at 150 mg/kg at 1 day before BMT
(Day −1). NS was intraperitoneally injected at a single dose
using a volume of 0.15 ml, similar to the volume used for SEB,
at 7 days before BMT (Day −7).
On Day 0 in Figure 1, three groups C57BL/6 mice after
different  pre-treatment  received  BMT  and  the  other  three
groups did not received BMT, then corneal transplantations
were performed on Day 7. All recipients were evaluated by
flow cytometry to determine if donor-derived hematopoietic
chimerisms were established (see below).
Corneal  transplantation:  Corneal  transplantation  used  a
BALB/c  corneal  graft  as  donor  and  a  C57BL/6  mice  as
recipient. Donor BALB/c central corneas were marked with a
2.0 mm diameter microcurette, excised with a vannas scissors
and placed in Optisol-GS (OGS; Bausch & Lomb Surgical,
Figure 1. Schematic presentation of the
study  design.  As  described  in  the
Methods,  C57BL/6  mice  received
BMCs on Day 0 from BALB/c donors.
Prior  to  BMT,  3  groups  of  C57BL/6
mice (20 mice/group) were pre-treated
with either SEB (Day −7), CYP (Day
−1)  or  Normal  Saline  (NS;  Day  −7).
Another 3 groups received either SEB
(Day −7), CYP (Day −1) or NS (Day -7)
without BMT were used as control. At 7
days post-BMT, each C57BL/6 mouse
received  a  corneal  transplant  from  a
BALB/c  donor.  Bone  marrow
chimerism in recipients was evaluated
on Days 14, 28, and 56. Other tests were
done  post-BMT  as  described  in  the
Results.
Molecular Vision 2012; 18:974-982 <http://www.molvis.org/molvis/v18/a102> © 2012 Molecular Vision
975Irvine, CA). Recipients were anesthetized by intraperitoneally
injection of ketamine and xylazine, and a 2.0 mm diameter
piece in the central cornea was excised from the right eye to
prepare the graft bed. The donor cornea was placed in the
recipient bed and secured with interrupted 11–0 nylon sutures
(Alcon,  Fort  Worth,  TX).  After  applying  an  antibiotic
ointment, the eye lids were closed for 3 days. Sutures were
removed  7  days  later.  The  degrees  of  graft  opacity  were
assessed using slit lamp biomicroscopy [22]. Briefly, graft
opacity was scored using an opacity scale from 0 to 5+. Zero
(0)  represents  a  clear  graft;  1+=minimal  superficial  (non-
stromal)  opacity;  2+=minimal  deep  stromal  opacity;
3+=moderate stromal opacity; 4+=intense stromal opacity;
5+=maximum  stromal  opacity.  A  score  >2+  indicated  a
cornea in rejection phase [14]. The mean corneal transplant
survival time for each group was also determined.
Characterization  of  bone  marrow  chimerism  by  flow
cytometry: Engraftment of donor BMCs was evaluated by
flow cytometry to determine the percentage of donor-derived
leukocytes in the peripheral blood of recipients on days 14,
28, and 56 after BMT [20]. Briefly, 500 μl of peripheral blood
was collected in a heparinized tube, RBCs were lysed with
erythrocyte lysis buffer and the cell suspension was washed
twice. Before specific monoclonal antibodies were added the
cell suspension was incubated with the Purified Rat anti-
mouse CD16/CD32 (Mouse BD Fc Block, BD PharMingen,
San  Diego,  CA)  for  15  min.  Donor-derived  cells  were
differentiated  using  a  phycoerythrin  (PE)-conjugated  anti-
MHC class II H2d antibody. The chimeric cell's lineage was
identified  by  double  staining  using  PE-labeled  anti-MHC
class II H2d in combination with peridinin chlorophyll protein
(PerCp)-conjugated  anti-CD4  mAb,  fluoresceine
isothiocyanate  (FITC)-conjugated  anti-CD8a  mAb  and
corresponding isotype controls. All antibodies were from BD
PharMingen  (San  Diego,  CA).  Fluorescent  signals  were
analyzed with a Becton Dickinson FACScalibur (San Jose,
CA). Data analysis used either Cell Quest (Becton Dickinson)
software; 10×106 events were acquired for each analysis.
Determination of chimerism: The percentage of peripheral
blood lymphocytes that expressed MHC class II in chimeric
mice was determined by labeling with antibodies to H2-b
(C57BL/6, host) and H2-d (BALB/c, donor). Because <100%
of  cells  expresses  MHC  class  II  antigens,  the  relative
percentage of donor-origin cells in chimeric recipients was
calculated by: proportion=[% donor cells/(% donor cells+%
host  cells)]  ×  100.  Based  on  isotype  control  staining,  we
defined  chimeric  recipients  as  those  mice  in  which  the
percentage of donor-origin cells in the peripheral blood was
>0.10% on days 14, 28, and 56.
Mixed lymphocyte reactions (MLR): MLR assays for BMT
recipients were done as described previously [23]. Responder
cells were prepared from bone marrow recipients on day 28
(day 21 after corneal transplantation). To detect proliferation
toward  alloantigens,  5×105  responder  cells  (splenocytes
prepared from C57BL/6 recipients) per well in 200 μl of
medium were co-cultured for 4 days with 5×105 irradiated (20
Gy) splenocytes prepared from C57BL/6 (isogeneic), BALB/
C (allogeneic), and CBA/1 (third-party) mice as stimulators.
Proliferative  responses  of  recipients’  splenocytes  were
determined  with  a  3-(4,5-dimethylthiazole-2-yl)-2,5-
biphenyl tetrazolium bromide (MTT) assay [18]. All cultures
were done in replicates of 5, and mean Optical density(OD
±SD) was measured at a wavelength of 570mm by ELISA
reader (Thermo MSS; Thermo).
Corneal allograft histopathological assessments: On day 21
(14 days after corneal transplantation), 2 eye globes from each
group of mice were embedded in paraffin, sectioned at 8 μm
thickness, and stained with hematoxylin and eosin (H&E).
Images were captured under a bright-field microscope (Leica
DM  4000B,  Leica  Microsystems  CMS  GmbH,  Wetzlar,
Germany) with a color CCD camera (Leica DFC 300 FX,
Leica Microsystems).
Statistical  analysis: Results were given  as    means±standard
deviations  (SDs).  Unless  stated  otherwise,  groups  were
compared  by  ANOVA,  with  group  effects  adjusted  by
Bonferroni’s  method.  Graft  survival  was  evaluated  by
generating  Kaplan–Meier  survival  curves,  with  group
comparisons made by a log-rank test. p-values <0.05 were
considered statistically significant. Statistical analysis used
SPSS 15.0 (SPSS, Inc. Chicago, IL).
RESULTS
Allogeneic  chimerism  in  bone  marrow  recipients:  As
described in the Methods and outlined in Figure 1, before
corneal  transplantation,  C57BL/6  (H-2b)  recipient  mice
received  BMT  using  BMCs  from  BALB/C  (H-2d)  donor
mice.  The  percentages  of  chimerism  in  recipients  were
determined  by  evaluating  their  peripheral  blood  cells  for
donor MHC class H-2d.
Figure 2 shows the establishment of donor chimerisms in
recipient mice on Days 0, 14, 28, and 56 after BMT. The
chimerism percentages were significantly higher in the SEB-
BMT and CYP-BMT groups than in the NS-BMT group on
Days 14 and 28. The chimerism percentages tended to decline
after Day 14, although the percentages in the SEB-BMT group
remained significantly higher than in the CYP-BMT and NS-
BMT groups by Day 56. Thus, SEB pre-treatment prolonged
allogeneic chimerism in recipients after BMT to a greater
extent than the other pre-treatments.
CD4+and CD8+T cells in the peripheral blood and spleen of
bone marrow recipients: Table 1 shows the percentages of
CD4+ and CD8+ T cells in peripheral blood or spleens from
the 6 groups of recipient mice at different times after BMT.
On days 14 and 56, the percentages of peripheral CD4+ T cells
were  significantly  decreased  in  the  SEB-  BMT  group
compared to the CYP-BMT, NS-BMT, and SEB groups. On
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976day 28 and day 56, the percentages of peripheral CD8+ T cells
were decreased in SEB-BMT group compared to the CYP-
BMT, NS-BMT, and SEB groups.
On day 14, the percentages of splenic CD4+ T cells were
lower in the SEB-BMT group than in the NS-BMT and SEB
groups. On day 28 and day 56, the percentage of splenic CD4+
T cells was significantly lower in the SEB-BMT group than
in the CYP-BMT, NS-BMT, or SEB group. Also on day 56,
the percentages of splenic CD8+ T cells were lower in the
SEB-BMT than in the CYP-BMT, NS-BMT, and SEB groups.
Donor-specific immunosuppression assessed by MLR: Mixed
allogeneic mice chimeras were assessed for donor-specific
immunosuppression  in  vitro  using  MLR.  Responder  cells
were prepared from the 6 pre-treatment groups of C57BL/6
recipient mice on day 28 . Stimulator cells were prepared from
C57BL/6  host  mice  (isogeneic),  BALB/c  donor  mice
(allogeneic) or CBA/1mice (third-party). Figure 3 shows the
Figure 2. Allogeneic chimerism in bone
marrow  recipients.  Peripheral  blood
samples  from  BMT  recipients  were
collected on Day 0, 14, 28, and 56 after
BMT.  Flow  cytometric  analysis  of
blood chimerism was determined using
a  monoclonal  antibody  against  donor
MHC  class  II  H-2d.  *  p<0.05,
significantly  different  from  NS-BMT
after  Bonferroni’s  adjustment  at  each
time  point.  †  p<0.05,  significantly
different  from  CYB-BMT  after
Bonferroni’s  adjustment  at  each  time
point.
TABLE 1. PERCENTAGES OF T CELL SUBSETS IN THE BLOOD AND SPLEENS OF RECIPIENT MICE.
    Peripheral blood Spleen
Group Days CD4+ CD8+ CD4+ CD8+
NS 14 30.2±1.9 16.9±0.9 26.8±1.0 11.1±0.8
  28 28.9 ±3.3 16.7±1.3 25.8 ±1.9 13.0±1.7
  56 27.9±1.9 17.6±1.8 27.3±1.8 12.9±1.8
CYP 14 27.8±3.5 15.8±2.5 25.2±3.0 16.9±1.9
  28 27.2 ±2.1 21.0±2.8 29.7±2.7 18.2±1.8
  56 27.5±2.5 19.1±1.4 32.6±2.4 13.2±1.6
SEB 14 28.5±1.5 22.0±2.1 24.8±2.7 13.3±0.7
  28 25.0 ±1.7 16.1±2.5 29.2±1.1 17.4±1.2
  56 23.4±1.8 18.0±1.2 27.2±1.3 17.4±1.1
NS-BMT 14 28.9±2.9 26.5±1.6 42.6±4.5 15.4±2.8
  28 19.2±2.6 13.7±1.3 34.4±3.5 22.0±1.5
  56 22.8±2.0 16.2±1.9 36.3±2.0 18.4±1.4
CYP-BMT 14 25.0±3.6* 21.6±2.2* 36.1±5.8* 14.1±2.5
  28 17.2±2.1* 12.2±0.6 31.5±6.6 21.2±3.3
  56 20.4±3.4* 16.7±1.1 29.5±3.4* 15.0±1.9*
SEB-BMT 14 19.0±2.5*†¢ 19.0±1.1*†¢ 27.9±8.4*¢ 14.4±1.5
  28 17.2±1.5 *¢ 13.2±1.2¢ 26.6±4.0 *†¢ 20.5±3.4¢
  56 19.6±0.9*†¢ 15.3±3.1¢ 27.7±2.3*†¢ 11.6±0.3*†¢
Note: NS, normal saline; CYP, cyclophosphamide; SEB, Staphylococcal Enterotoxin B; BMT, bone marrow transplantation. 

p<0.05, significantly different from NS-BMT group after Bonferroni’s adjustment at each time point; † p<0.05, significantly
different from CYP-BMT group after Bonferroni’s adjustment at each time point; ¢ p<0.05, significantly different from SEB
group after Bonferroni’s adjustment at each time point.
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977proliferative responses of responder cells from recipient mice
to the different stimulator cells.
Using cells from C57BL/6 mice as stimulators, there
were slight differences in proliferation among the responder
cells from the 6 pre-treatment groups; however, the overall
proliferative responses were minimal. In contrast, responder
cells  from  all  6  groups  exhibited  significant  proliferation
when stimulated by cells from third-party CBA/1 mice but
there were no significant difference among all groups. Using
stimulator cells from BALB/c donor mice, the proliferative
responses were significantly different among the responder
cells from the 6 pre-treatment groups; in particular, responder
cells  from  the  SEB-BMT  group  exhibited  the  lowest
proliferative responses to BALB/c donor cells. Thus, SEB
pre-treatment along with donor BMT induced a higher degree
of donor-specific immunosuppression in recipient mice.
Corneal allograft survival: As outlined in Figure 1, after the
different  pre-treatment  regimens,  C57BL/6  recipient  mice
received corneal transplants from BALB/c donors at Day 7
after BMT. Allograft survival was assessed up to Day 56. The
mean allograft survival times (in days) for the 6 groups of
recipient mice were: 7.4±1.5 for NS mice; 9.3±1.7 for CYP
mice; 11.2±2.1 for SEB mice; 9.0±2.2 for NS-BMT mice;
13.0±4.0 for CYP-BMT mice, and 20.3±7.6 for SEB-BMT
mice. These survival times were significantly different among
the 6 groups (p<0.05).
To  better  illustrate  these  differences,  Figure  4  shows
Kaplan–Meier survival curves for allograft survival. Corneal
allograft survival was the longest for mice pre-treated with
SEB and that received BMT from allograft donor mice. After
surgery, mice were given clinical examinations by slit lamp
microscopy every few days for 56 days for allograft survival
using  a  previously  described  scoring  system  to  evaluate
corneal  grafts  infiltration  (opacity)  [14].  Representative
images of corneal allografts are shown in Figure 5A.
Corneal  allograft  histopathological  assessments:  As
described in the methods, on day 21 (14 days after corneal
keratoplasty), 2 eyes from each group of mice were embedded
in paraffin, sectioned at 8 μm thickness, followed by H&E
staining.  These  sections  were  used  for  histopathological
assessments. Figure 5B shows representative H&E stained
sections for the 3 pre-treatment BMT groups. Different degree
of tissue damage was observed in the corneal allograft autopsy
specimens of the bone marrow recipients for the SEB-BMT,
CYP-BMT,  and  NS-BMT  groups.  However,  lymphocyte
infiltration and neovascularization were significantly reduced
in the SEB-BMT group compared to the CYP-BMT and the
NS-BMT groups (Figure 5B).
DISCUSSION
In this study, we addressed the question of whether a single
pre-treatment dose of the bacterial superantigen SEB before
BMT would provide a “window of opportunity” in recipient
mice in terms of inducing donor-specific immunosuppression
that  would  be  sufficient  to  enhance  the  establishment  of
chimerism and promote corneal allograft survival. Although
the  detailed  mechanisms  will  require  additional
investigations, our results showed that, as compared to pre-
treatment  with  either  CYP  or  NS,  SEB  pre-treatment  did
enhance the establishment of chimerism in BMT recipients
Figure 3. Mixed lymphocyte reactions
(MLR)  of  recipients  after  BMT.
Responder splenocytes  were  prepared 
from recipients at Day 28 after BMT.
These were co-cultured with irradiated
host (C57BL/6), donor (BALB/c), and
third-party  (CBA/1)   splenocytes   for
MLR assays. Results are the means ±
SDs  for  5  samples  for  each  group.  *
p<0.05, significantly different from NS-
BMT after Bonferroni’s adjustment for
each co-culture. † p<0.05, significantly
different  from  CYB-BMT  after
Bonferroni’s  adjustment  for  each  co-
culture. ¢ p<0.05, significantly different
from  SEB  group  after  Bonferroni’s
adjustment for each co-culture.
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978and prolonged the period of corneal allograft survival in these
recipient mice. These effects appeared to be due, at least in
part, to the effects of SEB to reduce reactive clones of CD4+
and/or CD8+ T cells in recipient mice.
Induction  of  donor-specific  tolerance  can  promote
allografts  to  be  accepted  across  MHC  barriers  without
requiring  chronic  immunosuppressive  therapy.  Among
numerous attempts to induce organ allograft tolerance, one
commonly accepted method involves the infusion of donor-
derived  cells,  particularly  BMCs,  associated  with  various
immunologic manipulations [24]. It has been demonstrated
that robust and lifelong donor-specific tolerance could be
achieved by the induction of chimerism in various animal
models. Recipient irradiation or other myeloablative therapy
is usually necessary to achieve engraftment success.
In  initial  attempts  with  rodents,  mixed  allogeneic
chimerism  was  established  using  lethal  irradiation  and
reconstitution  of  the  recipient  with  a  mixture  of  T-cell
Figure  4.  Corneal  allograft  survival.
Kaplan–Meier  survival  curves  for
corneal  allografts  transplanted  into
recipients after pre-treatment along with
BMT. PK=penetrating keratoplasty.
Figure 5. Clinical examination by slit lamp microscopy and histopathology of corneal allografts. A: Representative images of the corneal
allograft in each experimental group. B: Histopathological evaluation for corneal sections using H&E staining (40×). Graft rejection was
observed in the corneal necropsy specimens of the BMT recipients for the SEB-BMT, CYP-BMT, and NS-BMT groups by Day 21 after BMT
(Day 14 after corneal transplant). Lymphocyte infiltration and neovascularization were significantly decreased in the SEB-BMT group
compared to the CYP-BMT and NS-BMT groups.
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979depleted  host  and  donor  BMCs  [25].  Subsequently,  to
eliminate  the  need  for  lethal  irradiation,  ablation  used
different regimens of irradiation with or without cytotoxic
drugs and cytotoxic antibodies [26,27]. Thymic irradiation or
ablation with cytotoxic antibodies was also used in some cases
to create ‘‘space’’ in the recipient thymus, so that lasting
central tolerance could be achieved [28-30]. However, the
mechanisms  underlying  these  phenomena  are  not  fully
understood, and they still require administering potentially
harmful pre-conditioning regimens.
Recent reports have shown that SEB superantigens may
shape the T cell repertoire by the deletion or inactivation
(anergy) of reactive clones. Cellular unresponsiveness and
concomitant down-regulation of T cell receptors (TCR) and/
or co-receptors have been observed in some experimental
models of tolerance in vitro [31] and in vivo [32], suggesting
that  receptor  down-modulation  may  be  of  functional
significance for cellular inactivation. This may involve down-
regulation of TCRs and/or CD4 or CD8 co-receptors, as well
as other intracellular mechanisms, and would condition the
capacity of T cells to be reactivated.
Our previous studies with rats showed that· SEB could
prolong graft survival time by inducing T cell deletion and
non-specific  tolerance  in  high  risk  corneal  transplantation
[14-17].  Because  the  mechanisms  involved  are  different
between  SEB  pre-treatment  and  the  induction  of  donor-
derived  hematopoietic  chimerism,  the  question  arose  of
whether we could combine these two approaches to achieve
enhanced  immune  tolerance?  Our  current  experiments
demonstrated that the chimerism rate of donor derived BMC
engraftment  was  increased  in  the  SEB  pre-treated  group,
which  appeared  to  be  greater  than  that  with  CYP  pre-
treatment.  This  indicated  that  SEB  pre-treatment  could
promote BMC chimerism formation.
In  addition,  the  SEB  pre-treated  group  with  BMC
engraftment also exhibited a longer allograft survival time
compared to the NS pre-treated BMT group or SEB pre-
treated  without  BMT  group.  This  indicated  that  the
combination  of  SEB  pre-treatment  and  BMC  engraftment
could induce donor-derived specific immunosuppression and
promote  corneal  allograft  survival.  However,  our  animal
model  was  normal  penetrating  keratoplasty,  more  works
should be done to verify if this SEB pre-treated with BMC
engraftment could inhibited high-risk corneal grafts rejection.
Previous reports showed that either SEB treatment or
BMC  engraftment  could  manipulate  T  cell  responses,
particularly for the CD4+ and CD8+ populations. We also
observed that the CD4+ and CD8+ populations were affected
by the BMT after pre-treatments used. The percentage of
CD4+ or CD8+ T cells in peripheral blood in SEB-BMT group
was the lowest in all groups. Their percentages of splenic
CD4+  and  CD8+  T  lymphocytes  were  also  reduced
significantly.  Thus,  SEB  pre-treatment  could  reduce  the
populations of CD4+ and CD8+ T cells both in the peripheral
circulation and spleens of recipient mice after BMT, which
would  be  related  with  corneal  grafts  survival  time
prolongation.
Our results with MLR also showed reduced T lymphocyte
reactivity resulting from BMT after SEB pre-treatment. In
addition  to  reduced  lymphocyte  numbers  by  SEB  pre-
treatment, the lymphocytes proliferative capacity was also
reduced when stimulated by donor antigens. We called this
condition  immunosuppression  but  not  immune  tolerance
because the recipient mice corneal grafts rejection happened
at last. We also found that lymphocyte infiltration into the
corneal  grafts  was  significantly  decreased  when  recipient
treated  with  BMT  after  SEB  pre-treatment.  This  results
implied that SEB-BMT should have induced donor-specific
immunosuppression in mice receiving corneal transplants.
In summary, our results showed that a single-dose of SEB
pre-treatment could efficiently enhance the establishment of
chimerism by donor bone marrow engraftment, which could
induce  donor-specific  immunosuppression  and  prolong
corneal graft survival. This may have been related to CD4+
and  CD8+  T  cell  deletion.  The  mechanisms  of  how  SEB
combined with BMC transplantation affects cellular immune
responses need to be better understood.
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